| Combination of | |
|---|---|
| Atazanavir | Protease inhibitor |
| Ritonavir | Protease inhibitor (pharmacokinetic booster) |
| Clinical data | |
| Trade names | Ritovaz |
| Other names | Anzavir-R, ritonavir/atazanavir[1] |
| Routes of administration | By mouth[1] |
| ATC code | |
| Legal status | |
| Legal status |
|
Atazanavir/ritonavir (ATV/r) is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS.[1] It combines atazanavir and ritonavir.[1] It may be used instead of lopinavir/ritonavir.[2] It is taken by mouth.[1]
Side effects are generally minimal.[2] They may include abdominal pain, diarrhea, yellowish skin, muscle pains, and headache.[2] Greater care should be taken in people with underlying liver problems.[2] Use in pregnancy appears to be safe.[3] In the combination atazanavir functions as a protease inhibitor and ritonavir functions to increase levels of atazanavir.[2]
The combination was approved for use in India in 2012, and is pending approval in the United States As of 2017[update].[1] It is on the World Health Organization's List of Essential Medicines.[4]
References[edit]
- ^ a b c d e f "Atazanavir/ritonavir - Mylan Laboratories - AdisInsight". adisinsight.springer.com. Retrieved 29 June 2017.
- ^ a b c d e "Atazanavir + ritonavir (Addition) -- Adults". World Health Organization (WHO). Archived from the original on 3 February 2020. Retrieved 29 June 2017.
- ^ "Atazanavir/Ritonavir in Pregnancy". hivinsite.ucsf.edu. Archived from the original on 29 January 2018. Retrieved 10 December 2017.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
